COVID-19
Conditions
Keywords
COVID-19, Serum Amyloid A, Predictive markers
Brief summary
This study focuses on identifying genetic and biochemical markers (biomarkers) that could help predict the course of COVID-19. The investigators aim to analyze samples taken from the nasopharynx (nose and throat), saliva, and blood of patients with acute respiratory tract infections who come to the Outpatient Clinic of the Department of Respiratory Diseases at the Thomayer University Hospital. The main objectives include measuring the expression of the SAA1 gene (using quantitative RT-PCR) and conducting broader gene expression analysis (using RNA sequencing) in nasopharyngeal cells. At the same time, the investigators will examine the patients' DNA to identify rare genetic variants or common polymorphisms that may influence their immune response to the virus. The goal is to relate the values of SAA expression with clinical and radiological status and outcome of the patients. The investigators hypothesize, that SAA may predict the severity of the disease, need for hospitalizastion and outcome of the patients.
Detailed description
This cross-sectional study evaluated nasal SAA1 expression as a biomarker for early detection and severity assessment of respiratory tract infections, particularly in COVID-19 patients. A total of 369 participants presenting with infectious or non-infectious respiratory symptoms to the outpatient clinic were prospectively recruited between March 6, 2021, and June 26, 2023. Each patient underwent a single nasopharyngeal swab, which was used both for RT-qPCR testing of SARS-CoV-2 RNA and for SAA1 expression analysis, ensuring methodological consistency and direct comparability of results. Additionally, all participants underwent a chest X-ray, a comprehensive clinical examination, and routine blood and biochemistry testing. RNA Extraction and SAA1 mRNA Quantification: Nasal swabs were collected and stored under RNase-free conditions for RNA extraction. The relative expression of SAA1 was determined using real-time quantitative polymerase chain reaction (RT-qPCR).
Interventions
DIAGNOSTIC_TESTNasal swab to collect material for RT-PCR SAA evaluation
Nasal swab for parallel identification of SARS-Cov2 and SAA expression
Sponsors
Charles University, Czech Republic
Thomayer University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patients coming to the outpatient clinic and emergency room of the Department of Respiratory Diseases in Thomayer Hospital with symptoms of acute respiratory infection
Exclusion criteria
* Inability to sign the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The ability of SAA expression to predict clinical picture and outcome of the disease | 14 days | Levels of expression of SAA are related to the risk of hospitalization for COVID-19 |
| The ability of SAA expression to predict risk of death for COVID-19 | 3 months | Levels of expression of SAA are related to the risk of death |
Countries
Czechia
Outcome results
None listed